

# Efficacy of traditional Chinese medicine in treating cancer (Review)

JIAO NIE<sup>1\*</sup>, CHANGLIN ZHAO<sup>1,2\*</sup>, LI DENG<sup>1</sup>, JIA CHEN<sup>1</sup>, BIN YU<sup>1,3</sup>,  
XIANLIN WU<sup>1,4</sup>, PENG PANG<sup>1</sup> and XIAOYIN CHEN<sup>1</sup>

<sup>1</sup>Department of Traditional Chinese Medicine, Medical College of Jinan University; <sup>2</sup>Department of Oncology, Clifford Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong 510632;

<sup>3</sup>Clinical Institute, Jining Medical University, Jining, Shandong 272013; <sup>4</sup>Department of Pancreatic Disease Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510632, P.R. China

Received August 18, 2015; Accepted September 25, 2015

DOI: 10.3892/br.2015.537

**Abstract.** The morbidity associated with cancer has rapidly increased in recent years, and in the previous 5 years has had a tendency to be the leading cause of fatality compared with cardiovascular disease. Therefore, effective measures are required with an aim to reduce the incidence. Based on the results of clinical investigation, a multidisciplinary treatment strategy for cancer, which includes radiotherapy, chemotherapy, surgery, targeted therapy and immunotherapy, are prominently used in clinical practice. However, the therapies are insufficient due to multidrug resistance, adverse effects and the presence of the root of the cancer. Therefore, there is a necessity to develop more effective or adjunctive therapies for cancer prevention and treatment. Cancer is now widely recognized as a systemic humoral disease. Similarly, the function of herbal drugs is to modulate the whole body system in a more holistic way. Recently, herbal drugs have been applied to one of the efficient approaches for cancer therapy. Furthermore, there is evidence that various herbal medicines have been proven to be useful and effective in sensitizing the conventional agents against the various factors at the cellular and molecular levels that are associated with the occurrence of cancer and in prolonging survival time, alleviating side effects of chemotherapy and radiotherapy and improving the quality of life in cancer patients.

## Contents

1. Introduction
2. Inducing cellular apoptosis
3. Reversing multidrug resistance
4. Comprehensive efficacy on angiogenesis, cellular signaling pathway and metastasis
5. Regulating the immunomodulatory activities
6. Enhancing the efficacy, reducing toxicity and improving the quality of life for patients
7. Conclusion and future perspectives

## 1. Introduction

The database from the American Cancer Society (ACS) provides a summary of the current ACS cancer screening rates. Aside from skin cancer, the major incidence of cancer in 2015 was reported as cancer of the female breast, prostate cancers in males, and colorectal and lung cancer (1), and according to the study of Bray *et al* (2) reported in Lancet Oncology, the incidence of the total cancer cases will increase from 12.7 million new cases in 2008 to 22.2 million by 2030. Therefore, cancer specialists have determined that cancer is a life-threatening disease for future generations (3). Therefore, it is necessary to implement national cancer control plans to reduce the burden of cancer risk factors. Increasing attention has been paid to improve the palliative care and pain relief available to patients. Even though the skills of surgery, radiotherapy and chemotherapy, targeted therapy and immunotherapy have significantly improved, an increasing number of patients are selecting naturopathic therapy with traditional Chinese medicine (TCM), as they are considered to be multicomponents and multitarget agents exerting their therapeutic function in a more holistic way to the whole body system via restoration of the normal balance and flow in the body, which is believed to strengthen and enhance the endogenous resistance of the body to disease and individualization of therapy. In addition, the approval of three new herbal medicine-derived drugs (ixabepilone, trabectedin and temsirolimus) (4) in 2007 instigated the consideration of herbal medicines as a source for innovative

---

*Correspondence to:* Professor Xiaoyin Chen, Department of Traditional Chinese Medicine, Medical College of Jinan University, 601 Huangpu Road West, Guangzhou, Guangdong 510632, P.R. China  
E-mail: tchenxiaoyin@jnu.edu.cn

\*Contributed equally

**Key words:** cancer, herbal medicines, cellular and molecular level, survival time, side effects, quality of life

antitumor-targeted therapeutic agents. Worldwide, including Western countries, TCM has been more accepted for its efficacy in preventing and treating cancer. Investigations of targeted therapy with herbal medicines will potentially provide future discoveries in oncological research. It is estimated that the United States National Cancer Institute spends ~120 million USD each year on TCM-related research (5). While, based on the foundation of the system research of 'omics' approach (6), the occurrence of cancer is known to be based on various factors, several phases, multigenes and complicated signaling pathways (7,8). Cancer is considered a chronic health problem, similar to hypertension and diabetes by the World Health Organization, and therefore, the optimal effects of treatment involve improving life quality, prolonging survival time and alleviating side effects. Therefore, the concept of 'survival with cancer' has been suggested (9). The following is the evidence reported in preclinical or clinical trials that demonstrates the mechanism and efficacy of medicinal plants used as adjuvant treatment for cancer patients (also shown in Table I).

## 2. Inducing cellular apoptosis

Cell apoptosis is a form of programmed cell death that induces changes in cellular morphology and intracellular processes without inflammatory reactions. The procedures of apoptosis are formed as follows: Receiving apoptotic signals leads to cytomorphological alterations, the interaction between the intermolecular apoptotic proteins, activation of the caspase enzyme that acts upon cytoskeleton proteins, mitochondria, nuclear membrane or chromatin to cleave proteins and substrates, causing the DNA to fragment, releasing the cytoplasm enclosed by the plasma membrane, eventually leading to cell death (10-14). Currently, it is known that the extrinsic or death receptor pathway, the intrinsic or mitochondrial pathway and the perforin/granzyme pathway are the major apoptotic pathways to activate caspases (12,15-17). The apoptotic process is involved in the maintenance of tissue homeostasis, which can be triggered by a variety of stimuli, including cytokines, hormones, toxic insults and viruses. Once these stimuli seriously affect the self-homeostasis of the cells, the genes, including oncogenes, tumor-suppressor genes, suicide genes and DNA-repair genes, are activated and become cancerous resulting in the continuous division of the faulty cells. However, the herbal medicines have an important role in the prevention and treatment of cancer and execute their multiple therapeutic effects by inhibiting cancer-activating enzymes, stimulating a DNA repair mechanism and promoting production of protective enzymes, thus, showing anticancer effects.

Lin *et al* (18) investigated the cellular effects of the ethane extract of *Hedyotis Diffusa* Willd. (EEHDW) in the HT-29 human colon carcinoma cell. The study reported that EEHDW inhibited the growth of HT-29 cells by inducing cell morphological changes, which reduce the cell viability due to DNA fragmentation and loss of plasma membrane asymmetry, and also the collapse of mitochondrial membranes, the activation of caspase-9 and caspase-3 and the increase of the pro-apoptotic Bax to anti-apoptotic Bcl-2 ratio. Oxymatrine (19) is an isolated extract from the traditional Chinese herb *Sephora flavescent* Ait, and its anticancer effect was examined on human pancreatic cancer PANC-1 cells. The results showed its efficacy by

releasing cytochrome *c* and activating caspase-3 proteins. Additionally, it downregulated the expression of living and surviving genes and the Bax/Bcl-2 ratio was unregulated. The study by Guo *et al* (20) demonstrated that oxymatrine effectively suppressed the cell proliferation and phosphorylation of EGFR (Tyr845), decreased phospho-cofilin (Ser3) and phospho-LIMK1 (Thr508) without changing the total cofilin and LIMK1 expression to inhibit the migration and invasion of human gastric cancer cells. Hu *et al* (21) studied the efficacy of the TCM tubeimu on the MDA-MB-453 human breast cancer cell line. The study reported that the fragmentation of DNA could be observed by a fluorescence microscope at 72 h and apoptosis frequently increased when the cells were in a three-dimensional compared to a two-dimensional culture. The research regarding the emodin azide methyl anthraquinone derivative (22) demonstrates that cytotoxic effects (such as cell death) are through the arrest of the cell cycle and the induction of apoptosis in cancer cells. The overall molecular mechanisms of emodin include cell cycle arrest and apoptosis, promote the expression of hypoxia-inducible factor 1 $\alpha$ , glutathione S-transferase P and N-acetyltransferase, and induce glutathione phase I and II detoxification enzymes to inhibit angiogenesis, invasion, migration and chemical-induced carcinogen-DNA adduct formation. HER2/neu, CK2 kinase and p34cdc2 kinase were also inhibited in the human breast cancer cells.

## 3. Reversing multidrug resistance

Multidrug resistance (MDR) represents a prominent obstacle in cancer chemotherapy. Therefore, with the elucidation of the MDR mechanism, MDR has been associated with an adenosine triphosphate (ATP)-dependent decrease in cellular drug accumulation, which is attributed to the overexpression of certain ATP-binding cassette (ABC) transporter proteins (23). There are 9 human MDR proteins that are generally members of subfamily C in the ABC superfamily (23). Although their structures are different, they share a similar ATP-driven transport mechanism (24). However, due to their different locations, expression levels and activities, the drug resistance to chemotherapy is varied. Using the method for identifying the MDR mechanisms, there are three major mechanisms of drug resistance known in cells: i) Decreased water-soluble drug absorption, including folate antagonists and nucleoside analogues, which require transporters to enter cells; ii) various changes in cells occur that affect the capacity of cytotoxic drugs to kill cells, such as alterations in cell cycle, increased repair of DNA damage, reduced apoptosis and altered metabolism of drugs; and iii) increased energy-dependent efflux of hydrophobic drugs that can easily enter the cells by diffusion through the plasma membrane (25). P-glycoprotein (P-gp), which belongs to the first identified member of the ABC transporter superfamily of membrane transport proteins (26), represents the most common capability of resistance to hydrophobic anticancer drugs by actively extruding the drugs from the cells, including vinblastine, daunorubicin and paclitaxel. Therefore, patients with MDR tumor types often only have limited options, but can withstand significantly high doses (27). Thus, with the evidence that more new drugs are deriving from herbal medicines, quercetin, epigallocatechin gallate, curcumin, capsaicin and gingerol have

Table I. Chinese medicines commonly used in cancer treatment.

Active components	Tumor name	Efficacy according to bio-molecular levels	Preclinical or clinical evidence of anticancer activity
Extract of <i>Hedyotis Diffuse</i> Willd.	Human colon carcinoma cell	Induced cell apoptosis	Induced cell morphological changes, reduced cell viability, caused DNA fragmentation, loss of plasma membrane asymmetry, collapse of the mitochondrial membrane, activated caspase-9 and caspase-3
Oxymatrine (extract from <i>Sepphora Flavescens</i> Ait)	Human pancreatic cancer, (PANC-1 cell), human gastric cancer cell	Induced cell apoptosis, inhibited tumor metastasis	Inhibited cell viability, induced cell apoptosis, downregulated the survivin genes, upregulated the ratio of Bax/Bcl-2, released cytochrome c and activated caspase-3 proteins. Suppressed cell proliferation, decreased phosphorylation of EGFR (Tyr845), Cofilin (Ser3) and LIMK1 (Thr508)
Tubeimu of TCM	Human breast cancer cell (MDA-MB-453)	Induced cell apoptosis	Induced cell apoptosis and DNA fragmentation
<i>Paris saponin</i> VII extracted from <i>Trillium tschonoskii</i> Maxim	MCF-7/ADR cells	Reversed multidrug resistance, induced cell apoptosis	Suppressed cell viability, as well as triggered apoptosis and drug resistance of MCF-7/ADR cells, increased the expression of TNFR1, TRAILR1/DR4, TRAIL R2/DR5 and FADD, and activated PARP, caspase-8 and caspase-3. Reduced P-glycoprotein (P-gp) expression
Emodin azide methylanthraguinone derivative	Human breast cancer cells	Induced cell apoptosis, inhibited angiogenesis, tumor metastasis, reduced toxicity	Arrested cell cycle, induced cell apoptosis, promoted hypoxia-inducible factor-1 $\alpha$ , glutathione-S-transferase P and N-acetyltransferase expression, induced glutathione phase I and II detoxification enzymes to inhibit angiogenesis, invasion, migration and chemical-induced carcinogen-DNA adduct formation and inhibit the activity of HER2/neu, CK2 kinase and p34cdc2 kinase
Capsaicin and gingerol	KB-C2 cells	Reversed multidrug resistance	Enhanced P-gp to anti-drug efflux transporter and increased the cytotoxicity of vinblastine
Germacone (the main component of <i>Rhizma Curcuma</i> )	Human breast cancer cells (MCF-7/ADR)	Reversed multidrug resistance, induced cell apoptosis	Germacone and ADR increased the cytotoxicity compared to ADR alone and promoted cell apoptosis, downregulated the expression of anti-apoptotic proteins, p53 and Bax, inhibited the expression of P-gp by the inhibition of the multidrug resistance 1 (MDR1) gene promoter
Five tanshinones (including cryptotanshine and dihydrotanshine) isolated from <i>Salvia miltiorrhiza</i> (danshen)	SW620 AD300 colon cancer cells	Reversed multidrug resistance, enhanced efficacy	Decreased the digoxin efflux ratio, enhanced the cytotoxicity of doxorubicin and irinotecan in P-gp overexpressing SW620 AD300 colon cancer cells via increasing the intracellular accumulation of the P-gp substrate anticancer drugs, downregulated P-gp mRNA and protein expression and inhibited P-gp ATPase activity
Quinolones, indoloquinazoline alkaloids derived from <i>Evodia rupecarpa</i>	CEM/ADR5000 leukemia, porcine brain capillary endothelial cells	Reversed multidrug resistance	Alleviated the activity of P-gp modulators
Total extract of <i>Carthami Flos</i>	MDR KB-V1 cells	Reversed multidrug resistance and enhanced efficacy	Showed a function of drug resistance, enhanced their chemosensitivities and produced a general synergism in the cytotoxic effect

Table I. Continued.

Active components	Tumor name	Efficacy according to bio-molecular levels	Preclinical or clinical evidence of anticancer activity
Ethanol extract of <i>Scutellaria barbata</i>	Colon cancer cells, CRC mouse xenograft model	Induced cell apoptosis, inhibited angiogenesis and a signaling pathway	Induced cell apoptosis, inhibited angiogenesis <i>in vivo</i> , reduced tumor size without affecting body weight, suppressed the expression of key mediators of the pathway in tumor tissues, inhibited the expression of the target gene of the SHH signaling pathway, vascular endothelial growth A (VEGF-A)
Xiaotansanjie decoction	GCSCS	Inhibited angiogenesis and tumor growth, induced cell apoptosis	Regulated the expression of Notch-1, Hes1, VEGF and ki-67, inhibited the cell viability <i>in vivo</i> , inhibited the expression of i Notch-1 and Hes1 to inhibit tumor growth
Baicalin	MDA-MB -231 cells	Inhibited metastasis and a signaling pathway	Inhibited cell migration and invasion, suppressed tumor growth and the pulmonary metastasis via blocking the p38 mitogen-activated protein kinase (MAPK) activity and activated the inhibitor of p38 MAPK to decrease the expression of matrix metalloproteinase (MMP)-2, MMP-9, uPA and uPAR through the P38-MAPK signaling pathway
Pien Tze Huang	Mouse model of colorectal cancer	Inhibited tumor and angiogenesis, suppressed signaling pathways	Reduced the expression of angiogenic factors, including inducible nitric oxide synthase (iNOS), endothelial NOS, VEGF-A, basic fibroblast growth factor (bFGF), as well as their specific receptors, VEGFR2 and bFGFR, to inhibit tumor angiogenesis via suppression of multiple signaling pathways, such as STAT3, AKT and MAPKs
Ganoderic acid	Breast cancer cells	Induced cell apoptosis, inhibited tumor angiogenesis and metastasis to suppress a signaling pathway	Suppressed cell growth, tumor angiogenesis and invasion, stimulated Me (GA-Me) the production of tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ), downregulated the expression of various nuclear factor- $\kappa$ B (NF- $\kappa$ B) regulated genes [C-myc, cyclinD, Bcl-2, MMP-9, VEGF, interleukin (IL)-6 and IL-8] to modulate the NF- $\kappa$ B signaling pathway
TPA and saikosaponin $\alpha$	HepG2 cell	Suppressed signaling pathway to inhibit angiogenesis	Induced the phosphorylation of ERK, JNK and c-jun by activating the downstream transcriptional factors of the MAPK cascade (ATF2, c-jun, jun-B and c-fos), decreased the efficacy of PI5(INK4b)/p16(INK4a) RNAs, c-fos RNA protein and AP-1-related DNA-binding activity
Nobiletin	Human gastric adenocarcinoma AGS cells,	Inhibited angiogenesis by suppressing signaling pathways to inhibit tumor metastasis	Inhibited FAK and Pi3K/Akt activation to downregulate the enzyme activities, protein expression and messenger RNA levels of MMP-2 and MMP-9, Ras, C-Raf, Rac-1, Cdc42 and RhoA, increased the protein level of RhodB, decreased the phosphorylation and degradation of I $\kappa$ B $\alpha$ and NF- $\kappa$ B to inhibit the cell adhesion and invasion
Gegen Quinlian decoction	Human renal carcinoma cells	Inhibited angiogenesis and metastasis	Suppressed the enzyme activity of MMP2 to inhibit the expansion and neoangiogenesis of cancer



Table I. Continued.

Active components	Tumor name	Efficacy according to bio-molecular levels	Preclinical or clinical evidence of anticancer activity
Astragalus polysaccharides	S180 sarcoma-bearing mice	Enhanced immunomodulatory activities	Increased the IFN- $\alpha$ , FasL and GrB mRNA levels, improved the activity of intestinal intraepithelial $\gamma\delta$ T cytotoxicity of $\gamma\delta$ T cells and TNF- $\beta$ and IFN- $\alpha$ levels
Wogonin	SGC-7901 and MFC cells	Enhanced immunomodulatory activities	Exerted cytotoxicity to induce apoptosis of cancer cells, direct or indirect with DC, promoted the recruitment of DC, T and NK cells into tumor tissues to invert the expression levels of VEGF, B7H1 and RAE-1 $\epsilon$ , dephosphorylate STAT3 to inhibit its activation on tyrosine 705 to decrease the expression of B7H1 and MHC class I chain-related protein A and enhance calreticulin on the cell membrane
Mistletoe lectin-55	Colon cancer cell and colon cancer-bearing BALB/C mice	Enhanced immunomodulatory activities	Enhanced Ag-specific activation and proliferation of CD4 $^{+}$ and CD8 $^{+}$ T cells and increased the number of tumor Ag-specific CD8 $^{+}$ T cells with increasing production of IFN- $\gamma$ , increased activation of NK and $\gamma\delta$ T cells to delay colon cancer development
<i>Alocasia cucullata</i>	Mouse tumor models and mammalian cancer cells	Enhanced immunomodulatory activities	Enhanced the key cytokines <i>in vivo</i> , such as IL-2, IFN- $\gamma$ and TNF- $\alpha$ . <i>In vitro</i> , activated the differentiation of THP-1 into macrophage-like cells with specific macrophage surface markers, such as CD11b and CD14, and increased the induction of TNF- $\alpha$ and IL-1 $\beta$
<i>Ganoderma lucidum</i> (lucid ganoderma)	Cancer patients in a clinical trial, in mouse models <i>in vivo</i> and in cells <i>in vitro</i>	Enhanced immunomodulatory activities, induced cell apoptosis, antimetastasis and antiangiogenesis	Increased the mean concentration of plasma IL-2, IL-6 and IFN- $\gamma$ and decreased the levels of IL-1 and TNF- $\alpha$ in clinical trials, increased CD56 $^{+}$ (NK cells) and CD3 $^{+}$ (T lymphocyte), CD4 $^{+}$ (T helper cells) and CD8 $^{+}$ (T suppressor cells) <i>in vivo</i> and <i>in vitro</i> , cell cycle arrest, induced cell apoptosis, anti-invasion, antimigration, immunomodulation and antiangiogenesis
LQ (a mixture of Chinese medicinal herbs, comprising <i>Sinapisalba</i> , <i>Atractylodes macrocephala</i> , <i>Coix lacryma-jobi</i> and <i>Polyporus adusta</i> )	Lung cancer in mouse models	Induced cell apoptosis, antiangiogenesis, antimetastasis, enhanced efficacy and reduced toxicity	Inhibited tumor size and weight, exhibited antiangiogenic activity and prolonged the survival of tumor-bearing mice compared with DOX, inhibited lung cancer metastasis without weight loss and organ toxicity compared to CTX and DOX. <i>In vitro</i> , induced cell death on cancer cell lines compared to normal cell lines
Astragalus, turmeric, ginseng, Huachensu injection and Kanglaite injection	Clinical trials on patients and H22 cells	Enhanced the immune function, enhanced efficacy, reduced toxicity side effects and improved life quality	Suppressed tumor progression, increased the sensitivity of chemo- and radiotherapeutic treatment accompanied by lessening the damage and enhanced the immune system function from the preclinical and clinical studies, reduced cancer-related fatigue pain and the symptoms of cachexia, as well as resistance to respiratory tract infections and alleviation of gastrointestinal side effects (diarrhea, nausea and vomiting) and protection of the liver function, decreased the expression of survivin, increased the expression of caspase-9 in H22 cells

Table I. Continued.

Active components	Tumor name	Efficacy according to bio-molecular levels	Preclinical or clinical evidence of anticancer activity
Curcumin	MCF-7 cells, animal cancer, models, colorectal cancer cells (CRC)	Induced cell apoptosis, tumor metastasis, enhanced efficacy, improved life quality	Enhanced cell apoptosis, enhanced Bcl-2/Bax expression, improved the kidney function of creatinine/blood urea nitrogen and glutamic oxalacetic transaminase/glutamic pyruvic transaminase in the serum of animal trials with mitomycin C treatment, chemosensitized the activity of 5-FU-based chemotherapy <i>in vitro</i> , inhibited cell proliferation, metastasis and downregulated NF-κB-regulated gene activation
<i>Scutellaria baicalensis</i> and Qing-Shu-Yi-Qi-Tang	Lewis lung carcinoma (LLC) <i>in vivo</i> and <i>in vitro</i>	Enhanced immunity, reduced toxicity	<i>In vivo</i> , investigated in chemotherapy with cachectic symptoms, this combination increased the Th1/Th2 ratio and NK cytotoxicity and increased the monocyte chemoattractant protein-1 symptoms. <i>In vitro</i> , decreased the expression levels of NF-κB and muscle RING finger protein-1, decreased tumor masses and losses of carcass and/or gastrocnemius muscle
Chinese herbal medicine (CHM) ( <i>Radix Astragalus</i> , <i>Radix Adenophorae</i> , <i>Radix Ophiopogonis</i> , <i>Radix Glycyrrhizae Poria</i> and <i>Oldenlandia diffusa</i> )	Advanced non-small cell lung cancer patients	Enhanced efficacy, reduced toxicity, improved life quality	CHM combined with conventional chemotherapy reduced nausea and vomiting at toxicity grades of III-IV, prevented the decline of hemoglobin and platelets in patients under chemotherapy at toxicity grades of I-V, reduced chemotherapy toxicity, prolonged survival time, enhanced immediate tumor response and improved the Kamofsky performance status in advanced non-small cell lung cancer patients
Liu-Jun-Zi-Tang, PHY906, coumarin and aescine, ginseng, Huangqi, Ban Zhi Lian, TJ-48, Huachansu, Shenqi, fuzheng and Kanglaite injections	Patients following surgery and with chemo- or radiotherapy, improved life quality	Enhanced efficacy, reduced toxicity,	Improved the postoperation symptoms, such as fatigue, pain, appetite, diarrhea, nausea, vomiting and lymphedema in clinical trials, CHM in combination with chemo- or radiotherapy enhanced the efficacy and reduced the side effects and complications caused by chemo- and radiotherapy, including gastrointestinal side effects, liver function damage and bone marrow suppression

become promising candidates (28) as they overcome MDR potency in antitumor treatment. They act as MDR inhibitors, MDR modulators, MDR reversal agents or chemosensitizers to reverse the resistance against anticancer drug (25-30). Therefore, increasing studies are focusing on exploiting MDR reversal compounds from medicinal plants, as they have low or no side effects for use in cancer treatment (29), to bypass drug resistance in treating cancer, and eventually medicinal herbs may be applied in the future in cancer adjuvant therapy.

Capsaicin (8) and gingerol (8) have been reported to exhibit inhibitory effects on human P-gp. They increased the intracellular concentration of P-gp substrates by inhibiting this anticancer drug efflux transporter. MDR carcinoma KB-C2 cells were more susceptible to the cytotoxicity of vinblastine, as compared with vinblastine alone, when simultaneously treated with 50  $\mu$ M capsaicin or gingerol (31). Therefore, capsaicin and gingerol can partially reverse MDR in cells that express P-gp. Germacrone (32), the main component of *Rhizma curcuma*, was tested on MCF-7/adriamycin (ADR) MDR human breast cancer cells. The combination of germacrone and ADR increased the cytotoxicity when compared with ADR alone, and promoted cell apoptosis in a dose-dependent manner. The apoptotic effect was enhanced with ADR, as analyzed by downregulating the expression of anti-apoptotic proteins p53 and Bax. In addition, germacrone inhibited the expression of P-gp by inhibiting the MDR1 gene promoter. Tao *et al* (33) investigated the reversal of P-gp in colon cancer cells by five tanshinones isolated from *Salvia miltiorrhiza* (danshen), the result demonstrated that only cryptotanshinone and dihydrotanshinone decreased the digoxin efflux ratio in a dose-dependent manner and they enhanced the cytotoxicity of doxorubicin and irinotecan in P-gp overexpressing SW620 AD300 colon cancer cells by increasing the intracellular accumulation of the P-gp substrate anticancer drugs, which possibly downregulate the P-gp mRNA and protein expression and inhibit P-gp ATPase activity. Paris saponin VII (27), a type of saponin extracted from *Trillium tschonoskii* Maxim, dose-dependently suppressed cell viability, as well as triggered apoptosis and drug resistance of MCF-7/ADR cells. Furthermore, it also increased the expression of TNFR1, TRAILR1/DR4, TRAILR2/DR5 and FADD, and activated PARP, caspase-8 and caspase-3. By contrast, the P-gp expression and activity were reduced. Quinolones, indoloquinazoline alkaloids that are derived from the plant medicine *Evodia ruecarpa*, were tested on CEM/ADR5000 leukemia and porcine brain capillary endothelial cells. The results showed that the quinolones are moderate modulators of P-gp activity (34,35). Additionally, the drug resistance index of the total extract of *Carthami Flos* (CF) in MDR KB-V1 cells and its synergistic effects with other chemotherapeutic agents were studied. The results revealed that CF showed a drug resistance index, according to the classic isobologram equation. However, in combination with other chemotherapeutic agents, it enhanced their chemosensitivities and provided a general synergism of the cytotoxic effect (36).

#### 4. Comprehensive efficacy on angiogenesis, cellular signaling pathway and metastasis

Angiogenesis is the formation of new blood vessels and is a complex and regulated process that involves a number of

intercellular pro- and antiangiogenic signaling pathways. These pathways control the activity of blood vessel-associated cells, including endothelial cells (ECs) and pericytes (37), which is formed by the initiation of cell proliferation and migration in response to angiogenic stimulators: Vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), interleukin-8 (IL-8), placental growth factor (PIGF), transforming growth factor- $\beta$  (TGF- $\beta$ ), platelet-derived growth factor (PDGF), nitric oxide (NO), ephrins, angiopoietins, endothelins, integrins, cadherins, chemokines and Notch (37-39). The crosstalk among the overexpression of growth factors, hypoxia-inducible factor and the dysregulation of tyrosine kinase receptors is controlled by the phosphoinositide-3-kinase (PI3K)/Akt/mTOR (40), Ras/Raf/ERK/mitogen-activated protein kinase (MAPK) and hypoxia-inducible factor (HIF) regulatory pathways (41,42). The complicated formation of angiogenesis has provided a platform for tumor metastasis. The tumor hypoxia-induced epithelial-to-mesenchymal transition (EMT) also increased the metastatic phenotype of tumors (43). When oxygen and nutrients are supplied to the tumor cells, angiogenesis has an important role in the growth, invasion and metastasis for the tumor. Therefore, when the tumor microenvironment has been converted by angiogenesis, antiangiogenesis becomes a challenge for antitumor treatment. Therefore, numerous studies have inhibited tumor angiogenesis from four aspects (37,38,42): One is restraining the inhibitor of tumor angiogenesis degraded by the basilar membrane, and the second is inhibiting the inhibitor of tumor angiogenesis for increasing endotheliocytes. The third is preventing the activation of the growth factor that is associated with tumor angiogenesis. The final aspect is inhibiting the signaling pathways associated with tumor angiogenesis. However, the efficacy is unilateral, which may be insufficient and possibly generate drug resistance (44). Therefore, these problems highlighted the necessity for the exploitation of novel anticancer agents. However, there is numerous evidence (41) that has proved that plant-derived medicinal compounds may, in a number of cases, be at least as effective in blocking angiogenesis as the currently used synthetic drugs, which exhibit only a fraction of the side effects. The following are examples of the plant-derived medicinal compounds.

The TCM *Scutellaria barbata* is commonly used in cancer treatment. The ethanol extract of *Scutellaria barbata* (45) was able to induce apoptosis of the colon cancer cells and inhibit angiogenesis in a chick embryo chorioallantoic membrane model. In a colorectal cancer cell (CRC) mouse xenograft model *in vivo*, it could reduce tumor size without affecting the body weight and suppress the expression of key mediators of the Sonic hedgehog (SHH) pathway in tumor tissues. The expression of the important target gene of the SHH signaling pathway, vascular endothelial growth factor A (VEGF-A), was also inhibited, which has an important role in stimulating tumor angiogenesis. The study of the xiaotanshanjie decoction (46) in regulating the expression of Notch-1, Hes1, VEGF and Ki-67 was measured by western blotting and reverse transcription-polymerase chain reaction and the cell viability was measured by the MTT assay. The data revealed that cluster of differentiation (CD) 44<sup>+</sup> gastric cancer stem cells (GCSCS) showed more cell proliferation and VEGF secretion compared to CD44<sup>-</sup> cells *in vitro*,

whereas *in vivo*, the CD44<sup>+</sup> GCSCS had a high expression of Notch-1 and Hes1, which was positively associated with tumor growth. The study by Wang *et al* (47) reported that baicalin not only dose-dependently inhibited MDA-MB-231 cell migration and *in vitro* invasion, but also suppressed the growth of the tumor and the pulmonary metastasis via blocking p38 MAPK activity and activated the inhibitor of p38 MAPK which decreased the expression of matrix metalloproteinase-2 (MMP-2), MMP-9, urokinase plasminogen activator (uPA) and uPA receptor through the p38-MAPK signaling pathway. Pien Tze Huang (48) was tested on a mouse model of colorectal cancer and the treatment reduced the expression of angiogenic factors, including inducible NO synthase (NOS), endothelial NOS, VEGF-A, basic FGF (bFGF), as well as their specific receptors VEGFR2 and bFGFR, to inhibit the tumor angiogenesis via suppressing multiple signaling pathways, such as STAT3, AKT and MAPKs. In addition, based on the investigation of ganoderic acid Me (GA-Me) (49), the growth, angiogenesis and invasion of breast cancer cells were suppressed. By contrast, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) was stimulated. Furthermore, GA-Me downregulated the expression of various nuclear factor- $\kappa$ B (NF- $\kappa$ B)-regulated genes (C-myc, cyclin D, BCL-2, MMP-9, VEGF, IL-6 and IL-8) to modulate the NF- $\kappa$ B signaling pathway. Saikosaponin (50) was investigated on the HepG2 cell line and the results revealed that phosphorylation of ERK was significantly induced by TPA and saikosaponin  $\alpha$ , whereas the phosphorylation of JNK was induced only by TPA and the phosphorylation of P38 was not induced by either. This reaction was derived from the activation of the downstream transcriptional factors of the MAPK cascade (ATF2, c-jun, jun-B and c-fos). However, the inhibitor could decrease the efficacy of p15 (INK4b)/p16 (INK4a) RNAs, c-fos RNA protein and AP-1-related DNA-binding activity by TPA and saikosapanin, and c-jun phosphorylation was only reduced by TPA. A study of nobiletin (51) treatment of human gastric adenocarcinoma AGS cells reported an inhibition of the activation of focal adhesion kinase and PI3K/Akt, which are involved in the downregulation of the enzyme activities, and protein and messenger RNA levels of MMP-2, MMP-9, Ras, c-Raf, Rac-1, Cdc42 and RhoA. The protein level of RhoB was progressively increased, whereas treatment decreased the phosphorylation and degradation of inhibitor of  $\kappa$ Ba (IkBa) and the nuclear response element of NF- $\kappa$ B also exerted inhibitory effects on the cell adhesion and invasion. The TCM Gegen Qinlian decoction (52) significantly suppressed the enzyme activity of MMP-2 in human renal carcinoma cells to inhibit the expansion and neoangiogenesis of cancer.

## 5. Regulating the immunomodulatory activities

To an extent, tumors produce a number of tumor antigens, which are the primary triggers of the immune response. They are activated via a major histocompatibility complex (MHC) and the T cell response. In the process of immunosurveillance, they trigger T-cell activation to recruit other immune effector cells with the expression of co-stimulatory molecules and secretion of chemokines and cytokines to regulate different aspects of the immune response, including Th1 CD4 T cells

that activate CD8 T cells, and subsequently CD8 T cells are activated by direct antigen presentation, via MHC class I or via CD4 T-cell-mediated activation. The tumor cell is ultimately destroyed by direct cell-mediated cytotoxicity, as well as an indirect antibody complement-mediated cytotoxicity (53). However, the majority of tumors have been demonstrated to lose the expression of MHC molecules, resulting in the loss of presenting tumor antigens, thus evading T-cell recognition (40,53). In addition, when the balance of the immune checkpoint was destroyed, certain tumors upregulated inhibitory molecules to evade the immune response (40). Due to the strong heterogeneity of cancer, exploring novel effective drug targets and therapeutic strategies to overcome the problem is required. TCM, with a long history of treating various diseases through modulating the human immune response, offers a potential to be a remedy of the new immunomodulating regimen for cancer treatment. They exert broad immunostimulatory activities by recruiting and activating different types of immune cells, such as dendritic cells (DC), natural killer (NK) T-cells, T cells, macrophage, monocytes (54-56) and adjusting the production of cytokines (IFN- $\alpha$ , IL-2, IL-6 and IFN- $\gamma$ ) (54,57,58) to fight against the tumor cells.

In the study of astragalus polysaccharides (59) conducted on S180 sarcoma-bearing mice, the IFN- $\alpha$  FasL and GrB mRNA levels were increased and the activity of intestinal intraepithelial  $\gamma$ δT cells *in vivo* was also improved. The cytokine production and cytotoxicity of  $\gamma$ δT cells and the levels of TNF- $\beta$  and IFN- $\alpha$  were all markedly improved following treatment. The study of wogonin (54) treatment revealed that it exerted cytotoxicity, directly or indirectly with DC, to induce apoptosis of cancer cells (SGC-7901 and MFC cells). The treatment also promoted the recruitment of DC, T and NK cells into tumor tissues to invert the expression levels of vascular endothelial growth factor, B7H1, and RAE-1 $\epsilon$  in tumor tissues. Additionally, the treatment also dephosphorylated STAT3 to inhibit its activation on tyrosine 705 in tumor cells, which contributed to a decrease in the expression of B7H1 and MHC class I chain-related protein A and the enhancement of calreticulin on the cell membrane. Notably, these data indicated that wogonin could be used in collaboration with a DC vaccine or activated lymphocytes for tumor therapy. In addition, active chinese mistletoe lectin-55 was tested on colon cancer, and the results demonstrated that it enhanced antigen (Ag)-specific activation and proliferation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells and increased the number of tumor Ag-specific CD8<sup>+</sup> T cells with increasing production of IFN- $\gamma$ . Of note, the treatment with ACML-55 (58) also showed increased activation of innate lymphocytes, such as NK and  $\gamma$ δT cells. These immune responses significantly delayed colon cancer development in colon cancer-bearing BALB/C mice. *Alocasia cucullata* (AC) (57), a Chinese medicine, was investigated on mouse tumor models cultured in mammalian cells, and the results showed that its antitumor effect was closely associated with a strong induction of key cytokines *in vivo*, such as IL-2, IFN- $\gamma$  and TNF- $\alpha$ . AC activated the differentiation of THP-1, a human monocytic cell line, into macrophage-like cells *in vitro*, accompanied with specific macrophage surface markers, such as CD11b and CD14, and increased



the induction of TNF- $\alpha$  and IL-1 $\beta$ . All these data verified the potential of AC to be an alternative immunomodulating herbal remedy for anticancer treatment. *Ganoderma lucidum* (lucid ganoderma) (60), a traditional Chinese herb, has been used extensively in East Asia for one thousand years. Compounds of the extraction of *Ganoderma lucidum* mixed in PC-SPES (61,62) were administered to cancer patients in a clinical trial, in mouse models *in vivo* and in cells *in vitro*. In the prostate cancer patients, it improved the immunostimulating response with an increased concentration of plasma IL-2, IL-6 and interferon- $\gamma$ , and it enhanced the natural killer cell activity and decreased the production of plasma IL-1 and tumor necrosis factor- $\alpha$ . Simultaneously, in patients with advanced-stage cancer in a clinical trial, the statistical results showed that following surgery, the patients undergoing oral administration of lucid ganoderma extract for 12 weeks exhibited a significantly increased mean concentration of plasma IL-2, IL-6 and IFN- $\gamma$ , and significantly decreased levels of IL-1 and TNF- $\alpha$ . There was also a significant increase of CD56<sup>+</sup> (NK cells) and a small increase of CD3<sup>+</sup> (T lymphocyte), CD4<sup>+</sup> (T-helper cells) and CD8<sup>+</sup> (T-suppressor cells) with unchanged CD4:CD8 T-cell ratios, which were induced by the lucid ganoderma extract as compared to the baseline levels (63). With regards to the *in vitro* and *in vivo* studies, the anticancer mechanism of lucid ganoderma treatment against the growth of different cancer cells appeared to be mediated by cell cycle arrest, apoptosis, anti-invasion, antimigration, immunomodulation and antiangiogenesis (60). This evidence greatly supported the anticancer potential of lucid ganoderma.

## 6. Enhancing the efficacy, reducing toxicity and improving the quality of life for patients

Over a few decades, systemic chemotherapy and radiotherapy have been the optimal treatment options for the tumor patients owing to the limitations and drawbacks (9) of surgery, including patients that are diagnosed too late to undergo surgery and a number of complications occurring following surgery. However, the major problem in cancer chemoradiotherapy is the prolonged toxicity of the well-established chemical drugs or the radioactive rays that resulted in numerous side effects and complications, including pain, diarrhea, nausea, vomiting, hair loss and hepatotoxicity. Even in advanced stages, certain patients show a syndrome of cachexia (64), which leads to a poor quality of life. Thus, the complementary and alternative medicines have become a preference for patients. Consequently, there is certain evidence in pre-clinical and clinical trials that has proved that TCM can enhance the efficacy and reduce toxicity with chemoradiotherapy and improve the quality of life and functional status of patients.

The study by Zhang *et al* (65) compared the efficacy of the TCM herbal mixture LQ (66) (a mixture of Chinese medicinal herbs, comprising *Sinapis alba*, *Atractylodes macrocephala*, *Coix lacryma-jobi* and *Polyporus adustus*) against lung cancer in mouse models using doxorubicin (DOX) and cyclophosphamide (CTX). LQ inhibited the tumor size and weight measured directly, as well as by fluorescent-protein imaging in subcutaneous and orthotopic experimental metastasis and

angiogenesis lung cancer mouse models. Spontaneously, LQ had antiangiogenic activity and prolonged the survival of tumor-bearing mice compared with DOX. LQ was efficacious against primary and metastatic lung cancer without weight loss and organ toxicity, whereas CTX and DOX had opposing outcomes. *In vitro*, the study proved that LQ had the potential to induce cell death on cancer cell lines compared to normal cell lines. With regards to a review of Chinese herbal medicines (CHMs) (67) (astragalus, turmeric, ginseng, Huachansu injection and Kanglaite injection), data revealed that they have significant advantages in suppressing tumor progression, increasing the sensitivity of chemo- and radiotherapeutics accompanied by lessening the damage of the treatment and enhancing the immune system function of the organism from the preclinical and clinical studies. Additionally, they reduce cancer-related fatigue and pain and the symptoms of cachexia, as well as resistance to respiratory tract infections, alleviation of gastrointestinal side effects (diarrhea, nausea and vomiting) and protection of the liver function. The expression of survivin was also decreased. However, the expression of caspase-9 increased in H22 cells. Furthermore, in the study of Zhou *et al* (68), mitomycin C (MMC) and curcumin synergistically enhanced apoptosis in MCF-7 cells by activating the caspases and enhancing the expression of Bcl-2/Bax. Additionally, curcumin significantly improved the kidney function of creatinine/blood urea nitrogen and glutamic oxalacetic transaminase/glutamic pyruvic transaminase in the serum of animals undergoing MMC treatment. Furthermore, the study by Shakibaei *et al* (69) demonstrated that curcumin chemosensitized the activity of 5-FU-based chemotherapy on CRC accompanied with inhibition of cell proliferation, metastasis and downregulation of NF- $\kappa$ B-regulated gene activation. *Scutellaria baicalensis* (70) and Qing-Shu-Yi-Qi-Tang (70) were investigated on tumor-bearing mice with cachectic symptoms undergoing chemotherapy, and this combination increased the Th1/Th2 ratio and NK cytotoxicity, and the expression of monocyte chemoattractant protein-1 was also increased, whilst the expression levels of NF- $\kappa$ B and muscle RING finger protein-1 were decreased. Evidently the tumor masses and losses of carcass and/or gastrocnemius muscle were significantly decreased. In addition, data from a meta-analysis regarding CHM as an adjunctive therapy for advanced non-small cell lung cancer reported that CHM combined with conventional chemotherapy markedly reduced the nausea and vomiting at toxicity grade of III-IV and prevented the decline of hemoglobin and platelets in patients under chemotherapy at a toxicity grade of I-V (71). A systematic review suggested that CHM, as an adjuvant therapy, can reduce chemotherapy toxicity, prolong survival time, enhance immediate tumor response and improve the Karnofsky performance status in advanced non-small cell lung cancer patients. The review concluded that Liu-Jun-Zi-Tang, PHY906, coumarin and aescine were capable of improving the postoperation symptoms, such as fatigue, pain, appetite, diarrhea, nausea, vomiting and lymphedema in clinical trials (9). Additionally, ginseng, Huangqi, Ban Zhi Lian, TJ-48, Huachansu injection, Shenqi fuzheng injection and Kanglaite injection in combination with chemo- or radiotherapy were capable of enhancing the efficacy and diminishing the side effects and complications caused by chemo- and radiotherapy, including gastrointestinal side




Figure 1. Association of the anticancer mode of action with TCM in the tumor microenvironment. TCM anticancer activity involves targeting various steps (cell proliferation, angiogenesis, cell signaling pathways, invasion, metastasis and multidrug resistance) to inhibit tumor development, reduce the toxicity of other therapies to tumors in the microenvironments, and accordingly, to improve the quality of life for patients. TCM, traditional Chinese medicine; MRP, multidrug resistance protein; VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; P-gp, P-glycoprotein.

effects, liver function damage and even bone marrow suppression.

## 7. Conclusion and future perspectives

Cancer is a multifactorial and multistep disease that can change the tumor microenvironment, leading to alterations in tumor metabolism. The circulation of energy regarding glucose, lipid and amino acid metabolism and the formed metabolites (7) (such as lipids, amino acids, nucleotides, certain inflammatory cytokines and HIF) affected the cancer cell proliferation, autophagy, survival and invasion/metastasis and cellular signaling by blocking their required nutrients, their associated pathways (72) and inhibiting the activity of the regulated immune cells (73). However, the above evidence has proved that TCM has comprehensive advantages in treating cancer with regards to these aspects, which also presented a close association with each other (Fig. 1). Therefore, it may be advantageous to identify and develop novel natural compounds, active ingredients, single herbs and combination formulas or prescriptions in TCM with its multitargets and multisignaling pathways on the tumor, without significant toxicity compared to single utilization with other therapies. Even though the theory of TCM in treating cancer is in the early stages, in recent years, with the enhanced knowledge

of translational science and molecular biology, herbs and combination formulas have been reported to treat cancer as an effective therapy in preclinical or clinical trials. The database regarding the pharmacological activities and mechanisms of natural compounds revealed that tumors carried diverse driver gene mutations and crosstalked with different intracellular signals in the tumor microenvironment, leading to carcinogenesis (74). Therefore, it is imperative to explore the mechanism of TCM at the molecular levels to clarify the role of more TCM in curing disease, and additionally, to make a scientific foundation for internationalization of TCM. Based on the main principles of TCM regarding dialectic approaches, individualization and patients with different syndromes require treatment with different approaches. Therefore, TCM with regards to treating different syndromes in various individuals requires clarification. In recent years, there have been numerous studies of the Chinese medicinal compound monomer in the field of medical science, however, there are various components in the herbal medicines, and whether there is an interaction of the functional impacts between themselves by one approach or several ways remains to be elucidated. Therefore, further validation of the biodiversity of the herbal medicines in preclinical or clinical trials, either alone or in combination with existing therapy, is required to benefit more patients with cancer.

## References

- Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenko M, Fedewa S, Saslow D, Brawley OW and Wender R: Cancer screening in the United States, 2015: A review of current American cancer society guidelines and current issues in cancer screening. *CA Cancer J Clin* 65: 30-54, 2015.
- Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human Development Index (2008-2030): A population-based study. *Lancet Oncol* 13: 790-801, 2012.
- Adams C, Grey N, Magrath I, Miller A and Torode J: The World Cancer Declaration: Is the world catching up? *Lancet Oncol* 11: 1018-1020, 2010.
- Bailly C: Ready for a comeback of natural products in oncology. *Biochem Pharmacol* 77: 1447-1457, 2009.
- Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, Sun X, Zhou X, Guo Y, Xu Y, *et al*: Traditional Chinese medicine in cancer care: A review of controlled clinical studies published in chinese. *PLoS One* 8: e60338, 2013.
- Sen T and Samanta SK: Medicinal plants, human health and biodiversity: A broad review. *Adv Biochem Eng Biotechnol* 147: 59-110, 2015.
- Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR, *et al*: Cancer prevention and therapy through the modulation of the tumor microenvironment. *Semin Cancer Biol* Apr 10, 2015 (Epub ahead of print) doi: 10.1016/j.semcancer.2015.02.007.
- Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol* 71: 1397-1421, 2006.
- Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z and Han J: The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. *Biosci Trends* 9: 16-34, 2015.
- Jenkins VK, Timmons AK and McCall K: Diversity of cell death pathways: Insight from the fly ovary. *Trends Cell Biol* 23: 567-574, 2013.
- Elmore S: Apoptosis: A review of programmed cell death. *Toxicol Pathol* 35: 495-516, 2007.
- Boatright KM and Salvesen GS: Mechanisms of caspase activation. *Curr Opin Cell Biol* 15: 725-731, 2003.
- Romero A, Novoa B and Figueras A: The complexity of apoptotic cell death in mollusks: An update. *Fish Shellfish Immunol* 46: 79-87, 2015.
- Hengartner MO: The biochemistry of apoptosis. *Nature* 12: 770-776, 2000.
- Hensley P, Mishra M and Kyprianou N: Targeting caspases in cancer therapeutics. *Biol Chem* 394: 831-843, 2013.
- de Poot SA, Lai KW, van der Wal L, Plasman K, Van Damme P, Porter AC, Gevaert K and Bovenschen N: Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis. *Cell Death Differ* 21: 416-426, 2014.
- Chuang CH, Wang WJ, Li CF, Ko CY, Chou YH, Chuu CP, Cheng TL and Wang JM: The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. *Cell Death Dis* 5: e1220, 2014.
- Lin J, Chen Y, Wei L, Chen X, Xu W, Hong Z, Sferra TJ and Peng J: *Hedyotis Diffusa Willd* extract induces apoptosis via activation of the mitochondrion-dependent pathway in human colon carcinoma cells. *Int J Oncol* 37: 1331-1338, 2010.
- Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang B and Zheng S: Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. *J Exp Clin Cancer Res* 30: 66, 2011.
- Guo B, Zhang T, Su J, Wang K and Li X: Oxymatrine targets EGFR(p-Tyr845) and inhibits EGFR-related signaling pathways to suppress the proliferation and invasion of gastric cancer cells. *Cancer Chemother Pharmacol* 75: 353-363, 2015.
- Hu M, Zhao M, An C, Yang M, Li Q, Zhang Y, Suetsugu A, Tome Y, Yano S, Fu Y, *et al*: Real-time imaging of apoptosis induction of human breast cancer cells by the traditional Chinese medicinal herb tubeimu. *Anticancer Res* 32: 2509-2514, 2012.
- Hsu SC and Chung JG: Anticancer potential of emodin. *BioMedicine* 2: 108-116, 2012.
- Zhang YK, Wang YJ, Gupta P and Chen ZS: Multidrug resistance proteins (MRPs) and cancer therapy. *AAPS J* 17: 802-812, 2015.
- Wilkins S: Structure and mechanism of ABC transporters. *Fl000Prime Rep* 7: 14, 2015.
- Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. *Nat Rev Drug Discov* 5: 219-234, 2006.
- Leslie EM, Deeley RG and Cole SP: Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. *Toxicol Appl Pharmacol* 204: 216-237, 2005.
- Li Y, Fan L, Sun Y, Miao X, Zhang F, Meng J, Han J, Zhang D, Zhang R, Yue Z, *et al*: Paris saponin VII from *Trillium tschonoskii* reverses multidrug resistance of adriamycin-resistant MCF-7/ADR cells via P-glycoprotein inhibition and apoptosis augmentation. *J Ethnopharmacol* 154: 728-734, 2014.
- Cort A and Ozben T: Natural product modulators to overcome multidrug resistance in cancer. *Nutr Cancer* 67: 411-423, 2015.
- Eichhorn T and Efferth T: P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. *J Ethnopharmacol* 141: 557-570, 2012.
- Ugocsai K, Varga A, Molnár P, Antus S and Molnár J: Effects of selected flavonoids and carotenoids on drug accumulation and apoptosis induction in multidrug-resistant colon cancer cells expressing MDR1/LRP. *In Vivo* 19: 433-438, 2005.
- Nabekura T, Kamiyama S and Kitagawa S: Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. *Biochem Biophys Res Commun* 327: 866-870, 2005.
- Xie XH, Zhao H, Hu YY and Gu XD: Germacrone reverses Adriamycin resistance through cell apoptosis in multidrug-resistant breast cancer cells. *Exp Ther Med* 8: 1611-1615, 2014.
- Hu T, To KK, Wang L, Zhang L, Lu L, Shen J, Chan RL, Li M, Yeung JH and Cho CH: Reversal of P-glycoprotein (P-gp) mediated multidrug resistance in colon cancer cells by cryptotanshinone and dihydrotanshinone of *Salvia miltiorrhiza*. *Phytomedicine* 21: 1264-1272, 2014.
- Adams M, Mahringer A, Kunert O, Fricker G, Efferth T and Bauer R: Cytotoxicity and p-glycoprotein modulating effects of quinolones and indoloquinazolines from the Chinese herb *Evodia rutaecarpa*. *Planta Med* 73: 1554-1557, 2007.
- Adams M, Mahringer A, Bauer R, Fricker G and Efferth T: In vitro cytotoxicity and P-glycoprotein modulating effects of geranylated furocoumarins from *Tetradium daniellii*. *Planta Med* 73: 1475-1478, 2007.
- Wu JY, Yu ZL, Fong WF and Shi YQ: Chemotherapeutic activities of *Carthami Flos* and its reversal effect on multidrug resistance in cancer cells. *Afr J Tradit Complement Altern Med* 10: 36-40, 2013.
- Gordon MS, Mendelson DS and Kato G: Tumor angiogenesis and novel antiangiogenic strategies. *Int J Cancer* 126: 1777-1787, 2010.
- Bikfalvi A, Moenner M, Javerzat S, North S and Hagedorn M: Inhibition of angiogenesis and the angiogenesis/invasion shift. *Biochem Soc Trans* 39: 1560-1564, 2011.
- Ziche M and Morbidelli L: Molecular regulation of tumour angiogenesis by nitric oxide. *Eur Cytokine Netw* 20: 164-170, 2009.
- Jinushi M: Immune regulation of therapy-resistant niches: Emerging targets for improving anticancer drug responses. *Cancer Metastasis Rev* 33: 737-745, 2014.
- Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, *et al*: Broad targeting of angiogenesis for cancer prevention and therapy. *Semin Cancer Biol*: Jan 15, 2015 (Epub ahead of print) doi: 10.1016/j.semcancer.2015.01.001.
- Cook KM and Figg WD: Angiogenesis inhibitors: Current strategies and future prospects. *CA Cancer J Clin* 60: 222-243, 2010.
- Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresch DA, *et al*: VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. *Cancer Cell* 22: 21-35, 2012.
- Eikesdal HP and Kalluri R: Drug resistance associated with antiangiogenesis therapy. *Semin Cancer Biol* 19: 310-317, 2009.
- Wei L, Lin J, Xu W, Cai Q, Shen A, Hong Z and Peng J: *Scutellaria barbata* D. Don inhibits tumor angiogenesis via suppression of Hedgehog pathway in a mouse model of colorectal cancer. *Int J Mol Sci* 13: 9419-9430, 2012.
- Yan B, Liu L, Zhao Y, Xiu LJ, Sun DZ, Liu X, Lu Y, Shi J, Zhang YC, Li YJ, *et al*: Xiaotan Sanjie decoction attenuates tumor angiogenesis by manipulating Notch-1-regulated proliferation of gastric cancer stem-like cells. *World J Gastroenterol* 20: 13105-13118, 2014.



47. Wang XF, Zhou QM, Du J, Zhang H, Lu YY and Su SB: Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway. *Anticancer Agents Med Chem* 13: 923-931, 2013.
48. Shen A, Lin J, Chen Y, Lin W, Liu L, Hong Z, Sferra TJ and Peng J: Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways. *Oncol Rep* 30: 1701-1706, 2013.
49. Li F, Wang Y, Wang X, Li J, Cui H and Niu M: Ganoderic acids suppress growth and angiogenesis by modulating the NF- $\kappa$ B signaling pathway in breast cancer cells. *Int J Clin Pharmacol Ther* 50: 712-721, 2012.
50. Wen-Sheng W: ERK signaling pathway is involved in p15INK4b/p16INK4a expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a. *Oncogene* 22: 955-963, 2003.
51. Lee Y-C, Cheng TH, Lee JS, Chen JH, Liao YC, Fong Y, Wu CH and Shih YW: Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells. *Mol Cell Biochem* 347: 103-115, 2011.
52. Wang N, Feng Y, Cheung F, Wang X, Zhang Z and Feng Y: A Chinese medicine formula Gegen Qinlian decoction suppresses expansion of human renal carcinoma with inhibition of matrix metalloproteinase-2. *Integr Cancer Ther* 14: 75-85, 2015.
53. Spurrell EL and Lockley M: Adaptive immunity in cancer immunology and therapeutics. *Ecancermedicalscience* 8: 441, 2014.
54. Xiao W, Wu K, Yin M, Han S, Ding Y, Qiao A, Lu G, Deng B, Bo P and Gong W: Wogonin inhibits tumor-derived regulatory molecules by suppressing STAT3 signaling to promote tumor immunity. *J Immunother* 38: 167-84, 2015.
55. Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: Impact on clinical outcome. *Nat Rev Cancer* 12: 298-306, 2012.
56. Huang CF, Lin SS, Liao PH, Young SC and Yang C-C: The immunopharmaceutical effects and mechanisms of herb medicine. *Cell Mol Immunol* 5: 23-31, 2008.
57. Peng Q, Cai H, Sun X, Li X, Mo Z and Shi J: *Alocasia cucullata* exhibits strong antitumor effect in vivo by activating antitumor immunity. *PLoS One* 8: e75328, 2013.
58. Ma YH, Cheng WZ, Gong F, Ma AL, Yu QW, Zhang JY, Hu CY, Chen XH and Zhang DQ: Active Chinese mistletoe lectin-55 enhances colon cancer surveillance through regulating innate and adaptive immune responses. *World J Gastroenterol* 14: 5274-5281, 2008.
59. Sun S, Zheng K, Zhao H, Lu C, Liu B, Yu C, Zhang G, Bian Z, Lu A and He X: Regulatory effect of astragalus polysaccharides on intestinal intraepithelial  $\gamma$ 8T cells of tumor bearing mice. *Molecules* 19: 15224-15236, 2014.
60. Su ZY and Sheen, LY: An evidence-based perspective of *Ganoderma Lucidum* (Lucid Ganoderma) for cancer patients. In: *Evidence-based Anticancer Materia Medica*. Cho, W.C.S.(ed). Springer pp245-263, 2011.
61. de la Taille A, Hayek OR, Burchardt M, Burchardt T and Katz AE: Role of herbal compounds (PC-SPES) in hormone-refractory-prostate cancer: Two case reports. *J Altern Complement Med* 6: 449-451, 2000.
62. Hsieh TC and Wu JM: Mechanism of action of herbal supplement PC-SPES: Elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen-dependent LNCaP cells. *Int J Oncol* 20: 583-588, 2002.
63. Gao Y, Zhou S, Jiang W, Huang M and Dai X: Effects of ganopoly (a *Ganoderma lucidum* polysaccharide extract) on the immune functions in advanced-stage cancer patients. *Immunol Invest* 32: 201-215, 2003.
64. Donohoe CL, Ryan AM and Reynolds JV: Cancer cachexia: Mechanisms and clinical implications. *Gastroenterol Res Pract* 2011: 601434, 2011.
65. Zhang L, Wu C, Zhang Y, Liu F, Wang X, Zhao M and Hoffman RM: Comparison of efficacy and toxicity of traditional Chinese medicine (TCM) herbal mixture LQ and conventional chemotherapy on lung cancer metastasis and survival in mouse models. *PLoS One* 9: e109814, 2014.
66. Zhang L, Wu C, Zhang Y, Liu F, Zhao M, Bouvet M and Hoffman RM: Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer. *J Cell Biochem* 114: 2131-2137, 2013.
67. Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. *Biosci Trends* 4: 297-307, 2010.
68. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY, Huang S and Su SB: Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. *Eur J Cancer* 47: 2240-2247, 2011.
69. Shakibaei M, Kraehe P, Popper B, Shayan P, Goel A and Buhrmann C: Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. *BMC Cancer* 15: 250, 2015.
70. Wang H, Chan YL, Li TL and Wu CJ: Improving cachectic symptoms and immune strength of tumour-bearing mice in chemotherapy by a combination of *Scutellaria baicalensis* and Qing-Shu-Yi-Qi-Tang. *Eur J Cancer* 48: 1074-1084, 2012.
71. Li SG, Chen HY, Ou-Yang CS, Wang X-X, Yang Z-J, Tong Y and Cho WC: The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. *PLoS One* 8: e57604, 2013.
72. Singh SR, Tan M and Rameshwar P: Cancer metabolism: Targeting metabolic pathways in cancer therapy. *Cancer Lett* 356 (2 Pt A): 147-148, 2015.
73. Nowarski R, Gagliani N, Huber S and Flavell RA: Innate immune cells in inflammation and cancer. *Cancer Immunol Res* 1: 77-84, 2013.
74. Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E and Capaccioli S: Natural compounds for cancer treatment and prevention. *Pharmacol Res* 59: 365-378, 2009.